Business Segments · Net Income
Business Segments — Net Income
Neurocrine Biosciences Business Segments — Net Income increased by 28.8% to $197.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2405.1%, from $7.90M to $197.90M. Over 3 years (FY 2022 to FY 2025), Business Segments — Net Income shows an upward trend with a 45.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toNet Income
How to read this metric
An increase demonstrates growing profitability and the ability to generate sustainable returns for shareholders.
Detailed definition
The bottom-line profit remaining after all operating expenses, taxes, and non-operating costs are deducted from total re...
Peer comparison
The most fundamental profitability metric; compared across the industry to assess relative performance.
Metric ID:
nbix_segment_reportable_segment_net_incomeHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $38.63M | $38.63M | $38.63M | $38.63M | $62.43M | $62.43M | $62.43M | $62.43M | $43.40M | $65.00M | $129.80M | $103.10M | $7.90M | $107.50M | $209.50M | $153.70M | $197.90M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +61.6% | +0.0% | +0.0% | +0.0% | -30.5% | +49.8% | +99.7% | -20.6% | -92.3% | >999% | +94.9% | -26.6% | +28.8% |
| YoY Change | — | — | — | — | +61.6% | +61.6% | +61.6% | +61.6% | -30.5% | +4.1% | +107.9% | +65.2% | -81.8% | +65.4% | +61.4% | +49.1% | >999% |
Range$7.90M – $209.50M
CAGR+50.5%
Avg YoY Growth+222.5%
Median YoY Growth+61.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — net income?
- Neurocrine Biosciences (NBIX) reported business segments — net income of $197.90M in Q1 2026.
- How has Neurocrine Biosciences's business segments — net income changed year-over-year?
- Neurocrine Biosciences's business segments — net income increased by 2405.1% year-over-year, from $7.90M to $197.90M.
- What is the long-term trend for Neurocrine Biosciences's business segments — net income?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — net income has grown at a 45.8% compound annual growth rate (CAGR), from $154.50M to $478.60M.
- What does business segments — net income mean?
- The total profit remaining after all expenses and taxes have been paid.